ଗ୍ଲେକାପ୍ରେଭିର/ପିବ୍ରେଣ୍ଟାସଭିର

ଗ୍ଲେକାପ୍ରେଭିର/ପିବ୍ରେଣ୍ଟାସଭିର
Combination of
Glecaprevir	NS3/NS4A inhibitor
Pibrentasvir	NS5A inhibitor
Clinical data
Trade names	Mavyret, Maviret, others
AHFS/Drugs.com	monograph
MedlinePlus	a617039
data	EU EMA: yes; US DailyMed: Mavyret;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);

ଗ୍ଲେକାପ୍ରେଭିର/ପିବ୍ରେଣ୍ଟାସଭିର (ଜି/ପି), ବିକ୍ରୟ ନାମ ମ୍ୟାଲେରେଟ୍ ଏବଂ ମାଭରେଟ୍, ହେଉଛି ଏକ ସ୍ଥିର-ମାତ୍ରା ମିଶ୍ରଣ ଔଷଧ ଯାହା ହେପାଟାଇଟିସ ସି ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ^[୪] ଏଥିରେ ଗ୍ଲେକାପ୍ରେଭିର ଓ ପିବ୍ରେଣ୍ଟାସଭିର ଥାଏ ।^[୫] ^[୬] ^[୭] ^[୮] ସମସ୍ତ ଛଅ ପ୍ରକାରର ହେପାଟାଇଟିସ ସି ବିରୁଦ୍ଧରେ ଏହି ଔଷଧ କାମ କରେ । ଦିନ‌କୁ ଥରେ ଏହା ଖାଦ୍ୟ ସହିତ ପାଟିରେ ଦିଆଯାଏ । ^[୬] ^[୫]

ସବୁଠାରୁ ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ହେଉଛି ମୁଣ୍ଡବିନ୍ଧା, ତରଳ ଝାଡ଼ା ଏବଂ ଥକାପଣ ।^[୮] ^[୯] ହେପାଟାଇଟିସ ବି ଇତିହାସ ଥିବା ଲୋକଙ୍କଠାରେ ପୁନଃ ସକ୍ରିୟ ହୋଇପାରେ ।^[୧୦] ମଧ୍ୟମରୁ ଗୁରୁତର ଯକୃତ ରୋଗରେ ଆକ୍ରାନ୍ତ ବ୍ୟକ୍ତିଙ୍କୁ ଏହା ଦିଆଯାଇନଥାଏ । ^[୧୧] ଗ୍ଲେକାପ୍ରେଭିର ପ୍ରୋଟିନ NS3/4A ପ୍ରୋଟିଏଜ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ଓ NS5A ଅବରୋଧ କରି ପିବ୍ରେଣ୍ଟାସଭିର କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩]

୨୦୧୭ ଖ୍ରୀଷ୍ଟାବ୍ଦରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଏବଂ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଏହି ମିଶ୍ରଣକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା । ^[୭] ^[୩] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଅଛି । ^[୧୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୧୯ ସୁଦ୍ଧା ଏହାର ଏକ କୋର୍ଷର ମୂଲ୍ୟ ପ୍ରାୟ ୨୭,୬୦୦ ଡଲାର ଅଟେ ।^[୧୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୧୮ ସୁଦ୍ଧା ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୨୬,୦୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ । ^[୯]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ "Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy". Drugs.com. 10 October 2019. Archived from the original on 1 August 2020. Retrieved 30 March 2020.
↑ "Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 March 2020. Archived from the original on 1 August 2020. Retrieved 30 March 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Maviret EPAR". European Medicines Agency (EMA). 17 August 2017. Archived from the original on 30 December 2019. Retrieved 30 March 2020.
↑ "Mavyret- glecaprevir and pibrentasvir tablet, film coated". DailyMed. 28 January 2020. Archived from the original on 17 March 2020. Retrieved 30 March 2020.
↑ ^୫.୦ ^୫.୧ "Mavyret- glecaprevir and pibrentasvir tablet, film coated". DailyMed. 28 January 2020. Archived from the original on 17 March 2020. Retrieved 30 March 2020.
↑ ^୬.୦ ^୬.୧ "Maviret EPAR". European Medicines Agency (EMA). 17 August 2017. Archived from the original on 30 December 2019. Retrieved 30 March 2020.
↑ ^୭.୦ ^୭.୧ "FDA approves Mavyret for Hepatitis C" (Press release). U.S. Food and Drug Administration (FDA). 3 August 2017. Archived from the original on 30 March 2020. Retrieved 30 March 2020.
↑ ^୮.୦ ^୮.୧ "FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks". U.S. Food and Drug Administration (FDA). 26 September 2019. Archived from the original on 27 September 2019. Retrieved 1 October 2019.
↑ ^୯.୦ ^୯.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 620. ISBN 9780857113382.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 620. ISBN 9780857113382.
↑ "FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks". U.S. Food and Drug Administration (FDA). 26 September 2019. Archived from the original on 27 September 2019. Retrieved 1 October 2019.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑ "Mavyret Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 August 2020. Retrieved 16 November 2019.

[autogen1-1] ୧.୦ ^୧.୧ "Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy". Drugs.com. 10 October 2019. Archived from the original on 1 August 2020. Retrieved 30 March 2020.

[2] "Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 March 2020. Archived from the original on 1 August 2020. Retrieved 30 March 2020.

[EMA2017-3] ୩.୦ ^୩.୧ ^୩.୨ "Maviret EPAR". European Medicines Agency (EMA). 17 August 2017. Archived from the original on 30 December 2019. Retrieved 30 March 2020.

[Mavyret_FDA_label-4] "Mavyret- glecaprevir and pibrentasvir tablet, film coated". DailyMed. 28 January 2020. Archived from the original on 17 March 2020. Retrieved 30 March 2020.

[autogen2-5] ୫.୦ ^୫.୧ "Mavyret- glecaprevir and pibrentasvir tablet, film coated". DailyMed. 28 January 2020. Archived from the original on 17 March 2020. Retrieved 30 March 2020.

[autogen3-6] ୬.୦ ^୬.୧ "Maviret EPAR". European Medicines Agency (EMA). 17 August 2017. Archived from the original on 30 December 2019. Retrieved 30 March 2020.

[FDA2017-7] ୭.୦ ^୭.୧ "FDA approves Mavyret for Hepatitis C" (Press release). U.S. Food and Drug Administration (FDA). 3 August 2017. Archived from the original on 30 March 2020. Retrieved 30 March 2020.

[FDA2019-8] ୮.୦ ^୮.୧ "FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks". U.S. Food and Drug Administration (FDA). 26 September 2019. Archived from the original on 27 September 2019. Retrieved 1 October 2019.

[BNF76-9] ୯.୦ ^୯.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 620. ISBN 9780857113382.

[autogen6-10] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 620. ISBN 9780857113382.

[autogen7-11] "FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks". U.S. Food and Drug Administration (FDA). 26 September 2019. Archived from the original on 27 September 2019. Retrieved 1 October 2019.

[WHO21st-12] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Price2019-13] "Mavyret Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 August 2020. Retrieved 16 November 2019.

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୧]

[୨]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]